The Dutch pharmaceutical company Eurocept B.V. has acquired 100% of the share capital in the Danish specialty pharmaceutical company NordMedica A/S for an undisclosed consideration.
NordMedica A/S was founded in 2003 as a privately held specialty pharmaceutical company focused on the commercialization and marketing of niche pharmaceutical products. The company holds the rights to an oncology product under the brand names Amekrin®, Amsidine® and Amsidyl® in more than 25 countries. The product is based on a chemotherapy drug for the treatment of Acute Myeloid Leukemia (AML) and Acute Lymphatic Leukemia (ALL). All other assets and liabilities together with all employees were transferred to NordMedica International before the transaction.
Eurocept is a rapidly growing company active in the pharmaceutical and homecare market in the Benelux countries. Eurocept offers products and services that answer to pharmaceutical, technological and nursing needs in medical care as well as a unique combination of medical technology and distribution in the therapeutic areas of anesthesia, oncology, pediatrics, psychiatry, immunology, ADHD and urology.
Oaklins' team in Denmark acted as financial and strategic advisor to the seller in this transaction.
© 2018 Oaklins. All rights reserved. Oaklins is the collective trade name of independent member firms affiliated with Oaklins International Inc. For details of the nature of affiliation, please refer to www.oaklins.com/legal.